Table 1 Descriptive statistics for sarcoma in Western Australia, 1982–2016
1982–87 | 1988–93 | 1994–99 | 2000–05 | 2006–11 | 2012–16 | p-valuea | All | |
|---|---|---|---|---|---|---|---|---|
Soft tissue sarcoma | ||||||||
Number | 304 | 365 | 450 | 539 | 632 | 734 | 3024 | |
Sex | ||||||||
Male (%) | 140 (46.1) | 185 (50.7) | 245 (54.4) | 280 (51.9) | 337 (53.3) | 395 (53.8) | 0.226 | 1582 (52.3) |
Female (%) | 164 (53.9) | 180 (49.3) | 205 (45.6) | 259 (48.1) | 295 (46.7) | 339 (46.2) | 1442 (47.7) | |
Diagnostic age group | ||||||||
0–14 years (%) | 18 (5.9) | 17 (4.7) | 23 (5.1) | 19 (3.5) | 32 (5.1) | 23 (3.1) | 0.030 | 132 (4.4) |
15–24 years (%) | 18 (5.9) | 25 (6.8) | 27 (6) | 25 (4.6) | 27 (4.3) | 24 (3.3) | 146 (4.8) | |
25–64 years (%) | 179 (58.9) | 191 (52.3) | 225 (50) | 310 (57.5) | 346 (54.7) | 400 (54.5) | 1651 (54.6) | |
≥ 65 years (%) | 89 (29.3) | 132 (36.2) | 175 (38.9) | 185 (34.3) | 227 (35.9) | 287 (39.1) | 1095 (36.2) | |
Median age (IQR) | 54 (39–68) | 57 (37–73) | 59 (42–72) | 56 (42–71) | 58 (43–72) | 61 (47–74) | < 0.001 | 58 (42–72) |
Death on or prior to censor date (%) | 226 (74.3) | 246 (67.4) | 298 (66.2) | 289 (53.6) | 291 (46) | 196 (26.7) | < 0.001 | 1546 (51.1) |
Bone sarcoma | ||||||||
Number | 77 | 96 | 97 | 94 | 122 | 109 | 595 | |
Sex | ||||||||
Male (%) | 46 (59.7) | 57 (59.4) | 48 (49.5) | 52 (55.3) | 70 (57.4) | 68 (62.4) | 0.538 | 341 (57.3) |
Female (%) | 31 (40.3) | 39 (40.6) | 49 (50.5) | 42 (44.7) | 52 (42.6) | 41 (37.6) | 254 (42.7) | |
Diagnostic age group | ||||||||
0–14 years (%) | 18 (23.4) | 11 (11.5) | 17 (17.5) | 15 (16) | 20 (16.4) | 11 (10.1) | 0.252 | 92 (15.5) |
15–24 years (%) | 15 (19.5) | 23 (24) | 14 (14.4) | 15 (16) | 19 (15.6) | 27 (24.8) | 113 (19) | |
25–64 years (%) | 34 (44.2) | 49 (51) | 46 (47.4) | 43 (45.7) | 59 (48.4) | 45 (41.3) | 276 (46.4) | |
≥ 65 years (%) | 10 (13) | 13 (13.5) | 20 (20.6) | 21 (22.3) | 24 (19.7) | 26 (23.9) | 114 (19.2) | |
Median age (IQR) | 29 (16–55) | 33.5 (20–55.5) | 40 (19–59) | 43.5 (19–61) | 40.5 (20–63) | 42 (19–64) | 0.191 | 38 (18–61) |
Death on or prior to censor date (%) | 44 (57.1) | 52 (54.2) | 48 (49.5) | 53 (56.4) | 39 (32) | 28 (25.7) | < 0.001 | 264 (44.4) |
Gastrointestinal stromal sarcomab | ||||||||
Number | 0 | 35 | 60 | 67 | 61 | 223 | ||
Sex | ||||||||
Male (%) | 0 | 18 (51.4) | 26 (43.3) | 37 (55.2) | 38 (62.3) | 0.162 | 119 (53.4) | |
Female (%) | 0 | 17 (48.6) | 34 (56.7) | 30 (44.8) | 23 (37.7) | 104 (46.6) | ||
Diagnostic age group | ||||||||
0–14 years (%) | 0 | 0 0 | 0 | 0 | 0 | 0.510 | 0 | |
15–24 years (%) | 0 | 0 | 31 (52.7) | 0 | 0 | 114 (51.1) | ||
25–64 years (%) | 0 | 20 (57.1) | 37 (55.2) | 26 (42.6) | ||||
≥65 years (%) | 0 | 15 (42.9) | 29 (48.3) | 30 (44.8) | 35 (57.4) | 109 (48.9) | ||
Median age (IQR) | – | 56.5 (54–59) | 64 (45–78) | 64 (53.5–74.5) | 65 (50–75) | 68 (52–74) | 0.931 | 65 (52–75) |
Death on or prior to censor date (%) | 26 (74.3) | 37 (61.7) | 36 (53.7) | < 10 | < 0.001 | 107 (48) | ||
Kaposi’s sarcomab | ||||||||
Number | 14 | 44 | 31 | 24 | 34 | 147 | ||
Sex | ||||||||
Male (%) | 11 (78.6) | 39 (88.6) | 26 (83.9) | 20 (83.3) | 24 (70.6) | 0.303 | 120 (81.6) | |
Female (%) | 3 (21.4) | 5 (11.4) | 5 (16.1) | 4 (16.7) | 10 (29.4) | 27 (18.4) | ||
Diagnostic age group | ||||||||
0–14 years (%) | 0 | 0 | 0 | 0 | 0 (0) | 0.001 | 0 | |
15–24 years (%) | < 10 | < 10 | 0 | 0 | 13 (38.2) | 87 (59.1) | ||
25–64 years (%) | < 10 | 34 (77.3) | 20 (64.5) | 10 (41.7) | ||||
≥65 years (%) | < 10 | < 10 | 11 (35.5) | 14 (58.3) | 21 (61.8) | 60 (40.8) | ||
Median age (IQR) | 58.5 (30–72) | 39 (34–60.5) | 48 (36–71) | 72.5 (52.5–82.5) | 75 (62–83) | 63 (50–71) | < 0.001 | 56 (38–75) |
Death on or prior to censor date (%) | 12 (85.7) | 40 (90.9) | 23 (74.2) | 14 (58.3) | 10 (29.4) | < 0.001 | 99 (67.3) | |
Total | 395 | 507 | 611 | 717 | 840 | 919 | 3989 | |